The Russian telemedicine market grew by 50.16% in 2022, its volume amounted to 9.76 billion rubles. The market includes both classic telemedicine companies providing remote consultations of doctors, and services providing digital voluntary medical insurance as a service, as well as online psychotherapy platforms striving to become the core of the telemedicine system in the b2b segment.

Growth began during the lockdown period. The pandemic has opened up opportunities for telemedicine consultations and monitoring for both patients and doctors who used to be wary of online formats. Also, insurance companies began to include them in voluntary health insurance programs.

The telemedicine service "Sberbank Health" is on the first line of the rating among companies, it is the undisputed leader with a revenue of 5.2 billion rubles for the year and an increase of 40.5%. The second line is occupied by the telemedicine service "Doctis", whose revenue in 2022 amounted to 1.3 billion rubles and increased by 40.9%. According to the company, the second quarter turned out to be the most difficult, when the economic activity of the population sharply decreased, the usual promotion channels became unavailable and it was necessary to rebuild marketing activity, as well as adjust the launch dates of a number of new products.

In the third position, the online training service for medical workers "Aktion Medicine" is the leader of its segment with revenue of 1.2 billion rubles in 2022 (an increase of 16.2%).

The growth leader for the year was Budu startup, part of the Renaissance Insurance group, whose revenue grew by 528.57% over the year and amounted to 616 million rubles. As the companies note, many companies are faced with the need to cut costs, including in the field of employee care. On the other hand, more than half of Russians call the availability of voluntary medical insurance the second most important factor in choosing a job after the amount of remuneration, therefore, in the conditions of competition for qualified personnel, the startup "shot"

Despite the fact that the incidence of coronavirus infection has decreased, doctors helping to overcome the consequences of the disease are still in demand - neurologists, cardiologists and other specialists, market participants indicate. In the b2b segment, the demand for hybrid medical products has increased - the decision to visit a doctor in person or online saves employees' time and business funds for assistance.
Another important change in the requests of companies was the increased trend towards providing mental assistance to employees. Approximately every fourth contract included psychological assistance solutions.
Companies from the research segment faced difficulties in 2022. Thus, the prices of reagents in rubles have increased, many suppliers have terminated relations with Russian companies, the cost of attracting customers has increased due to the loss of previously effective advertising channels. Recall that many Western companies have curtailed their advertising activities in Russia: in particular, Google and Meta resources provided the lion's share of traffic. We had to change supply chains from West to East and develop new social networks to promote the brand and the Unim histology and immunohistochemistry laboratory.

Despite the steady growth, the industry is still far from maturity: many people already know about digital medicine, but only 8% of Russians actually used the service. Innovations in different fields should be implemented at different speeds: in medicine, it is lower due to the fact that we are talking about the safety of human life, and therefore any innovations should go through the stages of clinical research and thorough testing.

In addition, for the successful development of telemedicine, it is necessary to combine three main competencies: medical, IT and insurance. Those who lack expertise in a particular field are looking for partners, buying technologies, actively hiring specialists. There is a clear trend for the growth of leading companies at the expense of smaller players: not everyone was able to find their niche and business model, monetize interesting ideas, so small startups sell their technologies.